Physician profile
Michael Mccall
NPI 1073837845
$7,595.67
in general payments reported to CMS, 2019-2025
30 companies · $1,424 in 2025
The $1,424 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,106 · 2020: $347 · 2021: $804 · 2022: $1,335 · 2023: $1,216 · 2024: $1,363 · 2025: $1,424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,833 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,833.47 |
| Education | $169.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,786.85 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $796.58 | 2019-2025 | |
| Genzyme Corporation | $584.02 | 2019-2025 | |
| Amgen INC. | $570.72 | 2019-2025 | Otezla, Otezla, Amjevita |
| Janssen Biotech, INC. | $500.11 | 2023-2025 | Tremfya |
| Genentech USA, INC. | $417.64 | 2019-2024 | Erivedge |
| Leo Pharma INC. | $412.38 | 2019-2025 | Adbry, Spevigo |
| Sun Pharmaceutical Industries INC. | $377.37 | 2019-2025 | Blu-U, Odomzo |
| Ucb, INC. | $341.40 | 2019-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $299.18 | 2023-2024 | Sotyktu |
| Journey Medical Corporation | $268.15 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $253.17 | 2020-2025 | Dupixent, Libtayo |
| Pfizer INC. | $220.91 | 2019-2025 | |
| Organogenesis INC. | $184.69 | 2020-2025 | Affinity, Novachor, Via Matrix |
| Biofrontera INC. | $101.83 | 2019-2024 | Ameluz, Xepi, Bf-Rhodoled |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $70.30 | 2021-2023 | Taltz, Olumiant |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $65.39 | 2019-2021 | |
| Misonix INC | $62.95 | 2019 | |
| Krystal Biotech INC | $47.84 | 2023-2025 | Vyjuvek |
| Incyte Corporation | $42.91 | 2022-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $42.82 | 2023-2025 | Zoryve |
| Almirall LLC | $23.23 | 2023 | Klisyri |
| Vyne Pharmaceuticals INC. | $21.94 | 2021 | |
| Dermavant Sciences, INC. | $16.33 | 2023 | Vtama |
| Sandoz INC. | $14.95 | 2023 | Hyrimoz |
| Mimedx Group, INC. | $14.80 | 2025 | |
| Medline Industries Lp | $14.66 | 2019 | |
| Celgene Corporation | $14.28 | 2019 | |
| Springworks Therapeutics, INC. | $14.22 | 2025 | Gomekli |
| Dermira, INC. | $14.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mccall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.